Your browser is no longer supported. Please, upgrade your browser.
ASMB Assembly Biosciences, Inc. monthly Stock Chart
Assembly Biosciences, Inc.
Index- P/E- EPS (ttm)-1.64 Insider Own0.60% Shs Outstand35.51M Perf Week11.73%
Market Cap195.54M Forward P/E- EPS next Y-3.51 Insider Trans-7.80% Shs Float30.75M Perf Month-59.79%
Income-49.80M PEG- EPS next Q-0.90 Inst Own95.10% Short Float13.35% Perf Quarter-72.39%
Sales82.80M P/S2.36 EPS this Y6.60% Inst Trans2.26% Short Ratio4.28 Perf Half Y-68.12%
Book/sh7.62 P/B0.79 EPS next Y-125.00% ROA-15.90% Target Price- Perf Year-61.90%
Cash/sh7.30 P/C0.82 EPS next 5Y17.00% ROE-18.80% 52W Range4.78 - 27.84 Perf YTD-70.67%
Dividend- P/FCF- EPS past 5Y-1.80% ROI-37.30% 52W High-78.45% Beta0.72
Dividend %- Quick Ratio14.70 Sales past 5Y- Gross Margin- 52W Low25.52% ATR0.80
Employees140 Current Ratio14.70 Sales Q/Q723.80% Oper. Margin-64.90% RSI (14)26.70 Volatility4.80% 7.36%
OptionableYes Debt/Eq0.00 EPS Q/Q90.20% Profit Margin-60.10% Rel Volume1.31 Prev Close5.70
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume959.83K Price6.00
Recom1.70 SMA20-28.49% SMA50-53.59% SMA200-66.75% Volume1,256,515 Change5.26%
Nov-06-20Downgrade Jefferies Buy → Hold $30 → $10
Oct-19-20Initiated Truist Buy $55
Oct-16-19Initiated Mizuho Buy $20
Nov-19-18Initiated Leerink Partners Outperform $45
Oct-08-18Upgrade B. Riley FBR Neutral → Buy $42
Aug-08-18Initiated Robert W. Baird Outperform $74
Apr-13-18Downgrade Chardan Capital Markets Buy → Neutral $35 → $50
Jan-05-18Initiated B. Riley FBR, Inc. Neutral $35
Nov-08-17Initiated Jefferies Buy $50
May-30-17Initiated Chardan Capital Markets Buy $35
Nov-17-20 08:00AM  
Nov-16-20 08:00AM  
Nov-13-20 08:00AM  
Nov-06-20 04:41PM  
Nov-05-20 05:15PM  
Nov-02-20 08:00AM  
Oct-29-20 12:35PM  
Oct-20-20 08:00AM  
Oct-15-20 08:00AM  
Oct-13-20 01:14PM  
Oct-05-20 07:30AM  
Oct-02-20 04:30PM  
Sep-17-20 07:23AM  
Sep-04-20 04:30PM  
Aug-28-20 06:00AM  
Aug-27-20 08:00AM  
Aug-07-20 04:30PM  
Aug-05-20 07:55PM  
Jul-27-20 11:42PM  
Jul-20-20 07:53AM  
Jul-09-20 08:00AM  
Jul-02-20 04:30PM  
Jun-25-20 08:00AM  
Jun-24-20 08:55AM  
Jun-23-20 11:42AM  
Jun-22-20 08:45AM  
Jun-19-20 07:41AM  
Jun-18-20 04:01PM  
Jun-01-20 04:18PM  
May-27-20 08:00AM  
May-26-20 08:00AM  
May-19-20 04:05PM  
May-15-20 11:14AM  
May-13-20 10:58AM  
May-07-20 04:05PM  
May-06-20 06:33AM  
May-04-20 08:00AM  
May-01-20 05:00PM  
Apr-30-20 04:05PM  
Apr-06-20 08:00AM  
Mar-31-20 04:05PM  
Mar-30-20 08:00AM  
Mar-04-20 06:05PM  
Feb-20-20 12:31PM  
Feb-19-20 08:00AM  
Jan-28-20 06:00AM  
Dec-16-19 04:05PM  
Dec-12-19 06:30AM  
Dec-11-19 04:03PM  
Dec-10-19 11:11AM  
Dec-06-19 08:00AM  
Nov-18-19 08:00AM  
Nov-11-19 08:00AM  
Nov-08-19 04:13PM  
Nov-07-19 05:30PM  
Nov-06-19 04:40PM  
Oct-31-19 10:47AM  
Oct-30-19 06:58AM  
Oct-28-19 05:15PM  
Oct-18-19 11:02AM  
Oct-17-19 04:27PM  
Oct-16-19 07:05AM  
Sep-23-19 08:14AM  
Sep-15-19 09:16AM  
Aug-09-19 04:30PM  
Aug-07-19 08:00AM  
Aug-05-19 07:25PM  
Jul-17-19 01:08PM  
Jun-27-19 07:05AM  
Jun-25-19 04:05PM  
Jun-21-19 07:05AM  
Jun-14-19 04:41PM  
May-21-19 03:30PM  
May-09-19 07:45PM  
May-03-19 07:49AM  
Apr-29-19 10:31AM  
Apr-22-19 04:51PM  
Apr-15-19 01:37PM  
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in preclinical studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, immune-mediated and metabolic disorders, and oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs; and a collaboration and option agreement with Door Pharmaceuticals, LLC focused on the development of a hepatitis B virus core protein modulators. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stamm Luisa MChief Medical OfficerNov 09Sale5.104,39722,4047,603Nov 10 07:28 PM
McHutchison John GCEO and PresidentAug 07Sale21.8012,151264,917137,849Aug 10 04:34 PM
Colonno Richard JamesEVP & CSO, Virology OpsMar 31Sale15.047,812117,524137,009Mar 31 04:15 PM
Papkoff Jacqueline SybilSVP-CSO MicrobiomeMar 30Sale14.221,25417,83138,661Mar 31 04:16 PM
Papkoff Jacqueline SybilSVP-CSO MicrobiomeDec 13Sale21.001,46030,66222,915Dec 16 05:21 PM
Colonno Richard JamesEVP & CSO, Virology OpsDec 12Option Exercise7.0333,061232,419160,882Dec 16 05:17 PM
Colonno Richard JamesEVP & CSO, Virology OpsDec 12Sale25.0033,061826,578127,821Dec 16 05:17 PM